drugset
drugset / Trial / NCT04661943

Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma

NCT04661943 ↗

Phase 2 Completed 30 enrolled Ou Bai, MD/PHD
NaSingle-groupOpen-labelTreatment

Summary

A phase II，single arm，open-label study to assess Maintenance Therapy of Chidamide in Patients With Hepatitis B Virus（HBV）Positive Diffuse Large B-cell Lymphoma with complete response after completion of prior chemotherapy

Timeline

Start
2017-06-01
Primary completion
2024-07-31
Completion
2024-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Tucidinostat Small molecule 20 mg Oral

Indications

diffuse large B-cell lymphoma